Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay - A systematic review

European Journal of Clinical Pharmacology

Volumn 69, Issue 12, 2013, Pages 1985-1996

  Khan, Lateef Mohiuddin ^a  

^a King Abdulaziz University   (Saudi Arabia)

Author keywords

Adverse drug reactions; Hospital acquired ADR; Hospitalized patients Pharmacovigilance

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADVERSE DRUG REACTION; CANCER CHEMOTHERAPY; COMPUTERIZED PROVIDER ORDER ENTRY; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG COST; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GASTROINTESTINAL HEMORRHAGE; HARTWIG SCALE; HEALTH CARE SYSTEM; HEALTH DISPARITY; HEART FAILURE; HOSPITAL ACQUIRED ADVERSE DRUG REACTION; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; INCIDENCE; LENGTH OF STAY; MEDICAL ERROR; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHARMACOGENOMICS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; UREMIA;

ADULT; CHILD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY;

EID: 84892368789     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1563-z     Document Type: Review

References (118)

1. IMS (2011) The use of medicines in the United States: overview of 2010. IMS Institute for Healthcare Informatics, Danbury
2. IMS (2011) The hlobal use of medicines: outlook through 2015. IMS Institute for Healthcare Informatics, Danbury
3. Barach P, Small SD (2000) Reporting and preventing medical mishaps: lessons from non-medical near miss reporting systems. Br Med J 320:759-763
4. Blake DR (2003) Alternative prescribing and negligence. Br Med J 326:455
5. Wiffen P, Gill M, Edwards J, Moore A (2002) Adverse drug reactions in hospital patients. Bandolier Extra 1-15
6. World Health Organization (WHO) (1972) WHO Technical Report 498. Available at: www.who.int/tdr
7. Ritter M (2008) Minimizing harm: human variation and adverse drug reactions (ADRs). Br J Clin Pharmacol 65:451-452
8. Krizek TJ (2000) Surgical error: ethical issues of adverse events. Arch Surg 135:1359-1366
9. Thürmann PA (2001) Methods and systems to detect adverse drug reactions in hospitals. Drug Saf 24(13):961-968
10. Arulmani R, Rajendran SD, Suresh B (2008) Adverse drug reaction monitoring in a secondary care hospital in South India. Br J Clin Pharmacol 65:210-216
11. Ramesh M, Pandit J, Parthasarathi G (2003) Adverse drug reactions in a south Indian hospital-their severity and cost involved. Pharmacoepidemiol Drug Saf 12:687-692
12. Jose J, Rao PG (2006) Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res 54:226-233
13. Le J, Nguyen T, Law AV, Hodding J (2006) Adverse drug reactions among children over a 10-year period. Pediatrics 118:555-562
14. Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI (2008) Adverse drug reactions in adultmedical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol 65:396-406
15. Aagaard L, Christensen A, Hansen EH (2010) Information about adverse drug reactions reported in children: a qualitative review of empirical studies. Br J Clin Pharmacol 70:481-491
16. Easton L, Chapman C, Brien J (2004) Frequency and characteristics of hospital admissions associated with drug-related problems in paediatrics. Br J Clin Pharmacol 57(5):611-615
17. Eliasson E (2006) Ethnicity and adverse drug reactions. Br Med J 332:1163-1164
18. Lopez AD, Mathers CD, Ezzati M et al (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367:1747-1757
19. Bond CA, Raehl CL (2006) Adverse drug reactions in United States hospitals. Pharmacotherapy 26(5):601-608
20. Vora MB, Trivedi HR, Shah BK et al (2011) Adverse drug reactions in inpatients of internal medicine wards at a tertiary care hospital: A prospective cohort study. J Pharmacol Pharmacother 2:21-25
21. Pourseyed S, Fattahi F, Pourpak Z et al (2009) Adverse drug reactions in patients in an Iranian department of internal medicine. Pharmacoepidemiol Drug Saf 18:104-110
22. Khan LM, Al-Harthi SE, Saadah OI et al (2012) "Impact of pharmacovigilance on adverse drug reactions reporting in hospitalized internal medicine patients at Saudi Arabian teaching hospital". Saudi Med J 33(8):863-868
23. Davies EC, Green CF, Mottram DR et al (2006) Adverse drug reactions in hospital in-patients: a pilot study. J Clin Pharm Ther 31:335-341
24. Davies EC, Green CF, Taylor S, Williamson PR et al (2009) Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 4(2):e4439. doi:10.1371/journal. pone.0004439
25. Suh D-C, Woodall BS, Shin S-K et al (2000). Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 34:1373-1379
26. Calderón-Ospina C, Bustamante-Rojas C (2010) The DoTS classification is a usefulway to classify adverse drug reactions: a preliminary study in hospitalized patients. Int J Pharm Pract 18(4):230-235
27. Mohebbi N, Shalviri G, Salarifar M et al (2010) Adverse drug reactions induced by cardiovascular drugs in cardiovascular care unit patients. Pharmacoepidemiol Drug Saf 19(9):889-894
28. Harugeri A, Parthasarathi G, Ramesh M et al (2011) Frequency and nature of adverse drug reactions in elderly in-patients of two Indian medical college hospitals. J Post Grad Med 57(3):189-195
29. Doshi MS, Patel PP, Shah SP et al (2012) Intensive monitoring of adverse drug reactions in hospitalized patients of two medical units at a tertiary care teaching hospital. J Pharmacol Pharmacother 3(4):308-313
30. Süsskind M, Thürmann PA, Lüke C et al (2012) Adverse drug reactions in a complementary medicine hospital: a prospective, intensified surveillance study. Evid Based Complement Alternat Med 2012:320760. doi:10.1155/2012/320760
31. Tangiisuran B, Davies JG, Wright JE et al (2012) Adverse drug reactions in a population of hospitalized very elderly patients. Drugs Aging 29(8):669-679
32. Sikdar KC, Dowden J, Alaghehbandan R et al (2012) Adverse drug reactions in elderly hospitalized patients: a 12-year populationbased retrospective cohort study. Ann Pharmacother 46(7-8):960-971
33. Lobo MG, Pinheiro SM, Castro JG et al (2013) Adverse drug reactionmonitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil. BMC Pharmacol Toxicol 14:5. doi:10.1186/2050-6511-14-5
34. Ponte ML, Ragusa M, Armenteros C et al (2013) Importance of pharmacovigilance in current medical practice (abstract, in Spanish). Medicina (B Aires) 73(1):35-38
35. Camargo AL, Cardoso Ferreira MB et al (2006) Adverse drug reactions: a cohort study in internal medicine units at a university hospital. Eur J Clin Pharmacol 62:143-149
36. Chien JY, Ho RJ (2011) Drug delivery trends in clinical trials and translational medicine: Evaluation of pharmacokinetic properties in special populations. J Pharm Sci 100:53-58
37. Demoly P, Bousquet J (2001) Epidemiology of drug allergy. Curr Opin Allergy Clin Immunol 1:305-310
38. Rawlins MD (2004) NICE work-providing guidance to the British National Health Service. N Engl J Med 351(3):1381-1385
39. Castro-Pastrana LI, Carleton BC (2011) Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge. J Popul Ther Clin Pharmacol 18:e76-e88
40. Napoleone E (2010) Children and ADRs (Adverse Drug Reactions). Ital J Pediatr 36:4
41. Impicciatore M (2003) Pharmacogenomic can give children safer medicines. Arch Dis Child 88(4):366
42. Leeder JS (2003) Developmental and pediatric pharmacogenomics. Pharmacogenomics 4:331-341
43. Lindell-Osuagwu L, Korhonen MJ, Saano S et al (2009) Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 34:277-287
44. Smyth RM, Gargon E, Kirkham J, Cresswell L et al (2012) Adverse drug reactions in children-a systematic review. PLoS One 3:e24061
45. Buajordet I, Wesenberg F, Brors O (2002) Langslet A Adverse drug events in children during hospitalization and after discharge in a Norwegian University Hospital. Acta Paediatr Int J Paediatr 91:88-94
46. Impicciatore P, Choonara I, Clarkson A et al (2001) Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 52(1):77-83
47. Weiss J, Krebs S, Hoffmann C et al (2002) Survey of adverse drug reactions on a pediatric ward: A strategy for early and detailed detection. Pediatrics 110:254-257
48. Easton-Carter KL, Chapman CB, Brien JAE (2003) Adverse drug reactions in paediatrics: Are we getting the full picture? J Pharm Pract Res 33:106-110
49. Neubert A, Dormann H, Weiss J et al (2004) The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Safety 27:1059-1067
50. Fattahi F, Pourpak Z, Moin M, et al (2005) Adverse drug reactions in hospitalized children in a department of infectious diseases. J Clin Pharmacol 45:1313-1318
51. Haffner S, von Laue N, Wirth S (2005) Thurmann PADetecting adverse drug reactions on paediatric wards-intensified surveillance versus computerized screening of laboratory values. Drug Safety 28:453-464
52. dos Santos DB, Coelho HL (2006) Adverse drug reactions in hospitalized children in Fortaleza, Brazil. Pharmacoepidemiol. Drug Saf 15:635-640
53. Jha N, Bajracharya O, Namgyal T (2007) Prevalence of adverse drug reactions with commonly prescribed drugs in different hospitals of Kathmandu valley. Kathmandu Univ M J 5:504-510
54. Ganeva M, Gancheva T, Lazarova R et al (2007) A prospective study of adverse drug reactions in a dermatology department. Methods Find Exp Clin Pharmacol 29:107-112
55. Baniasadi S, Fahimi F (2008) Shalviri G Developing an adverse drug reaction reporting system at a teaching hospital. Basic Clin Pharmacol Toxicol 102:408-411
56. Farrokhi S, Pourpak Z, Fattahi F et al (2009) Adverse drug and medical instrument reactions in a pediatric intensive care unit. Pharmacoepidemiol Drug Saf 18(8):761-762
57. Dos Santos L, Martinbiancho JK Silva MM et al (2009) Adverse drug reactions in general pediatrics units of a university hospital. Lat Am J Pharm 28:695-699
58. Agarwal S, Classen D, Larsen G et al (2010) Prevalence of adverse events in pediatric ICUs in the United States. Pediatr Crit Care Med 11(5):568-578
59. Gallagher RM, Mason JR, Bird KA et al (2012) Adverse drug reactions causing admission to a paediatric hospital. PLoS One 7(12):e50127. doi:10.1371/journal.pone.0050127
60. Khan LM, Al-Harthi SE, Saadah OI (2013) Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR. Saudi Pharm J 21:261-266
61. Oehme A-K, Rashed AN, Hefele B et al (2012) Adverse drug reactions in hospitalized children in Germany are decreasing: results of a nine year cohort-based comparison. PLoS One 7(9):e44349
62. Holbrook AM, Pereira JA, Labiris R et al (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165(10):1095-1106
63. Office for National Statistics, England (2012) Cancer Statistics Registrations. Available at: http://www.ons.gov.uk)
64. Kaushal R, Shojania KG, Bates DW (2003) Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med 163:1409-1416
65. Hartwig SC, Siegel J, Schneider PJ (1992) Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 49:2229-2232
66. Temple ME, Robinson RF, Miller JC et al (2004) Frequency and preventability of adverse drug reactions in pediatric patients. Drug Saf 27:819-829
67. Bavdekar SB, Karande S (2006) National pharmacovigilance program. Indian Pediatr 43:27-32
68. Oshikoya KA, Njokanma OF, Chukwura HA et al (2007) Adverse drug reactions in Nigerian children. Paediatr Perinat Drug Therapy 8:81-88
69. Priyadharsini R, Surendiran A, Adithan C et al (2011) A study of adverse drug reactions in pediatric patients. J Pharmacol Pharmacother 2:277-280
70. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 279:1200-1205
71. Gurwitz JH, Field TS, Harrold LR et al (2003) Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289(9):1107-1116
72. Wester K, Jonnson AK, Sigset O et al (2008) Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 65:573-579
73. Tramèr MR, Moore RA, Reynolds DJ et al (2000) Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 85(1-2):169-182
74. Paessens BJ, von Schilling C, Berger K et al (2011) Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients. Ann Oncol 22(10):2310-2319. doi:10.1093/annonc/mdq759
75. Ihbe-Heffinger A, Paessens B, Berger K et al (2013) The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care-an observational analysis on non-smallcell lung cancer patients. Support Care Cancer 21(6):1665-1675
76. Niraula S, Seruga B, Ocana A et al (2012) The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 30(24):3012-3019. doi:10.1200/JCO.2011.40. 3824
77. Seruga B, Sterling L, Wang L et al (2011) Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 29(2):174-185. doi:10.1200/JCO. 2010.31.9624
78. Nebeker JR, Barach P, Samore MH (2004) Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 140:795-801
79. Aagaard L, Hansen EH (2010) Adverse drug reactions reported for systemic antibacterials in Danish children over a decade. Br J Clin Pharmacol 70:765-768
80. Clavenna A, Bonati M (2009) Adverse drug reactions in childhood: A review of prospective studies and safety alerts. Arch Dis Child 94:724-728
81. Clavenna A, Bonati M (2009) ADR Epidemiology in Paediatrics. M&B 28:503-504
82. Schumock GT, Thornton JP (1992) Focusing on the preventability of adverse drug reactions. Hosp Pharm 27:538
83. Hallas J, Harvald B, Gram LF et al (1990) Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 228(2):83-90
84. Imbs JL, Pletan Y, Spriet A (1998) Assessment of preventable iatrogenic drug therapy: Methodology. Round Table No 2 at Giens XIII (in French). Therapie 53(4):365-370
85. Hakkarainen KM, Hedna K, Petzold M et al (2012) Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions-ameta-analysis. PLoS One 7(3):e33236. doi:10.1371/journal.pone.0033236
86. Kanjanarat P, Winterstein AG, Johns TE et al (2003) Nature of preventable adverse drug events in hospitals: A literature review. Am J Health-Syst Pharm 60:1750-1759
87. Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, et al (2007) Drug-related problems in hospitals: A review of the recent literature. Drug Saf 30(5):379-407
88. Passarelli MC, Jacob-Filho W, Figueras A (2005). Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging 22(9):767-777
89. Farcas A, Sinpetrean A, Mogosan C et al (2010) Adverse drug reactions detected by stimulated spontaneous reporting in an internal medicine department in romania. Eur J Intern Med 21(5):453-457. doi:10.1016/j.ejim.2010.05.014
90. Ahern F, Sahm LJ, Lynch D et al (2013) Determining the frequency and preventability of adverse drug reaction-related admissions to an Irish University Hospital: a cross-sectional study. Emerg Med J [Epub ahead of print]
91. Pirmohamed M, James S, Meakin S et al (2004) Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15-19
92. Davies EC, Green CF, Mottram DR et al (2007) Adverse drug reactions in hospitals. Narrat Rev Curr Drug Saf 2:79-87
93. Rodriguez-Monguio R, Otero MJ, Rovira J (2003) Assessing the economic impact of adverse drug effects. Pharmacoeconomics 21(9):623-650
94. Lundkvist J, Jönsson B (2004) Pharmacoeconomics of adverse drug reactions. Fundam Clin Pharmacol 18:275-280
95. Bates DW, Spell N, Cullen DJ et al (1997) The costs of adverse drug events in hospitalized patients. JAMA 277:307-311
96. Egbring M, Far E, Knuth A et al (2011) Performance of different data sources in identifying adverse drug events in hospitalized patients. Eur J Clin Pharmacol 67(9):909-918. doi:10.1007/s00228-011-1020-9
97. Wu C, Bell CM, Wodchis WP (2012) Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study. Drug Saf 35(9):769-781
98. Burgess CL D'Arcy C, Holman J et al (2005) Adverse drug reactions in older Australians, 1981-2002. Med J Aust 182:267-270
99. U.S. Department of Health and Human Services (1999) Centers for Medicare and Medicaid Services. Expanded modified Medicare provider analysis and review Department of Health and Human Services, Baltimore
100. Wasserfallen J, Livio F, Buclin T et al (2001) Rate, type, and cost of adverse drug reactions in emergency department admissions. Eur J Intern Med 12:442-444
101. Routledge PA, O'Mahony MS, Woodhouse KW (2003) Adverse drug reactions in elderly patients. Br J Clin Pharmacol 57:121-126
102. Trontell A (2004) Expecting the unexpected-drug safety, pharmacovigilance, and the prepared mind. N. Engl. J. Med. 2004; 351, 1385-1387
103. Topol EJ (2004) Failing the public health: rofecoxib, Merck, and the FDA [editorial]. N Engl J Med 351:1709
104. Furberg CD, Levin AA, Gross PA et al (2006) The FDA and drug safety. Arch Intern Med 166:1938-1942
105. Kesselheim AS, Avorn J (2007) The role of litigation in defining drug risks. JAMA 297:308-311
106. Kuehn BM (2006) IOM: overhaul drug safety monitoring. JAMA 296:2075-2076
107. Psaty BM, Burke SP (2006) Protecting the health of the public-Institute of Medicine recommendations on drug safety. N Engl J Med 355:1753-1755
108. Curfman GD, Morrissey S, Drazen JM (2006) Blueprint for a stronger Food and Drug Administration. N Engl J Med 355:1821
109. Du W, Tutag Lehr V, Lieh-Lai M, et al (2012). An algorithm to detect adverse drug reactions in the neonatal intensive care unit: a new approach. J Clin Pharmacol 53:87-95
110. Classen DC, Resar R, Griffin F et al (2011) 'Global trigger tool' shows that adverse events in hospitals may be ten times greater than previously measured. Health Aff (Millwood) 30(4):581-589. doi:10.1377/hlthaff.2011.0190.
111. Erratum in Health Aff (Millwood). 2011 June; 30(6):1217
112. Hung SI, Chung WH, Liu ZS et al (2010) Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11:349-356
113. Aihara M (2011) Pharmacogenetics of cutaneous adverse drug reactions. J Dermatol 38(3):246-254
114. Thong BY, Tan TC (2011) Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 71(5):684-700
115. Daly AK (2010) Pharmacogenetics and human genetic polymorphisms. Biochem J 429:435-449
116. Daly AK (2012) Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu Rev Pharmacol Toxicol 52:21-35
117. Agewall S, Cattaneo M, Collet JP et al (2013). Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. doi: 0.1093/eurheartj/eht042
118. Rashid S, Rajan D, Iqbal J et al (2012) Inappropriate use of gastric acid suppression therapy in hospitalized patients with Clostridium difficile-associated diarrhea: a ten-year retrospective analysis. ISRN Gastroenterol 2012:902320. doi:10.5402/2012/902320